The value of pemetrexed for the treatment of malignant pleural mesothelioma: A comprehensive review

Anticancer Research

Volumn 33, Issue 9, 2013, Pages 3553-3562

  Boons, Christel C L M ^a   Van Tulder, Maurits W ^a,b,c   Burgers, Jacobus A ^b   Beckeringh, Jan Jacob ^d   Wagner, Cordula ^e,f   Hugtenburg, Jacqueline G ^a,c  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d Westwijk Pharmaceutics BV   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f NETHERLANDS INSTITUTE FOR HEALTH SERVICES RESEARCH   (Netherlands)

Author keywords

Chemotherapy; Health economics; Mesothelioma; Pemetrexed; Quality of life; Review; Treatment outcome

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; GEMCITABINE; NAVELBINE; PEMETREXED; RALTITREXED;

ALOPECIA; ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONJUNCTIVITIS; COST EFFECTIVENESS ANALYSIS; DEHYDRATION; DIARRHEA; DRUG COST; DRUG RESPONSE; ECONOMIC EVALUATION; FATIGUE; HUMAN; HYPERTENSION; LETHARGY; LEUKOPENIA; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PALLIATIVE THERAPY; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; STOMATITIS; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM; VOMITING;

CHEMOTHERAPY; HEALTH ECONOMICS; MESOTHELIOMA; PREMETREXED; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; GLUTAMATES; GUANINE; HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS; QUALITY OF LIFE;

EID: 84885000013     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Chen SE and Pace MB: Malignant pleural mesothelioma. Am J Health Syst Pharm 69: 377-385, 2012.
2. Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, Dienemann H, Galateau-Salle F, Hennequin C, Hillerdal G, Le Pechoux C, Mutti L, Pairon JC, Stahel R, van Houtte P, van Meerbeeck J, Waller D and Weder W: Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 35: 479-495, 2010.
3. Grosso F and Scagliotti GV: Systemic treatment of malignant pleural mesothelioma. Future Oncol 8: 293-305, 2012.
4. Tsao AS, Wistuba I, Roth JA, Kindler HL: Malignant pleural mesothelioma. J Clin Oncol 27: 2081-2090, 2009.
5. Dutch Cancer Statistics. Comprehensive Cancer Centre of the Netherlands (IKNL). 2011. Available from: http:// www. cijfersoverkanker.nl/. Last accessed June 28, 2013.
6. Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, Nicholson AG, O'Brien M, Peake M, Rudd R, Snee M, Steele J, Girling DJ, Nankivell M, Pugh C and Parmar MK: Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): A multicentre randomised trial. Lancet 371: 1685-1694, 2008.
7. Berghmans T, Paesmans M, Lalami Y, Louviaux I, Luce S, Mascaux C, Meert AP and Sculier JP: Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 38: 111-121, 2002.
8. D'addario G, Pintilie M, Leighl NB, Feld R, Cerny T and Shepherd FA: Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A meta-analysis of the published literature. J Clin Oncol 23: 2926-2936, 2005.
9. Dillon A: Pemetrexed for the Treatment of Malignant Pleural Mesothelioma. London: National Institute for Health and Clinical Excellence; 2010.
10. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Malignant Pleural Mesothelioma. V.2.2012. NCCN.org. National Comprehensive Cancer Network; 2011. Available from: http://www.nccn.org/professionals/ physician-gls/f-guidelines.asp. Last accessed June 28, 2013.
11. Stahel RA, Weder W, Lievens Y and Felip E: Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21: 126-128, 2010.
12. European Public Assessment Report Alimta Product Information. European Medicines Agency (EMEA). 2012. Available from: http://www.ema.europa.eu. Last accessed June 28, 2013.
13. Cost Prognosis of Pemetrexed (Alimta®) in Combination with Cisplatin for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma. Diemen: Health Care Insurance Board (CVZ), 2009 (Kostenprognose van opname van pemetrexed (Alimta®) in combinatie met cisplatine bij de indicatie lokaal gevorderd of gemetastaseerd niet-kleincellig longcarcinoom).
14. Moore S, Darlison L and Tod AM: Living with mesothelioma. A literature review. Eur J Cancer Care 19: 458-468, 2010.
15. Dundar Y, Bagust A, Dickson R, Dodd S, Green J, Haycox A, Hill R, McLeod C, Walley T: Pemetrexed disodium for the treatment of malignant pleural mesothelioma: A systematic review and economic evaluation. Health Technol Assess 11: 1-90, 2007.
16. Green JA, Dundar Y, Dodd SR, Dickson RC and Walley T: Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma. Cochrane Database of Systematic Reviews, 2007.
17. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C and Paoletti P: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644, 2003.
18. van Meerbeeck JP, Gaafar R, Manegold C, van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C and Giaccone G: Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23: 6881-6889, 2005.
19. Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, Serra M, Muzio A, Carbone R, Buosi R, Galbusera V, Piccolini E, Giaretto L, Rebella L and Mencoboni M: Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 19: 370-373, 2008.
20. Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del CG, Ceribelli A, Bearz A, Morenghi E, Cavina R, Marangolo M, Parra HJ and Santoro A: Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 24: 1443-1448, 2006.
21. Favaretto AG, Aversa SM, Paccagnella A, Manzini VP, Palmisano V, Oniga F, Stefani M, Rea F, Bortolotti L, Loreggian L and Monfardini S: Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: A multicentric phase II study. Cancer 97: 2791-2797, 2003.
22. Kalmadi SR, Rankin C, Kraut MJ, Jacobs AD, Petrylak DP, Adelstein DJ, Keohan ML, Taub RN and Borden EC: Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: A phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer 60: 259-263, 2008.
23. Katirtzoglou N, Gkiozos I, Makrilia N, Tsaroucha E, Rapti A, Stratakos G, Fountzilas G and Syrigos KN: Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: A phase II study. Clin Lung Cancer 11: 30-35, 2010.
24. Kovac V, Zwitter M, Rajer M, Marin A, Debeljak A, Smrdel U and Vrankar M: A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma. Anticancer Drugs 23: 230-238, 2012.
25. Scagliotti GV, Shin DM, Kindler HL, Vasconcelles MJ, Keppler U, Manegold C, Burris H, Gatzemeier U, Blatter J, Symanowski JT and Rusthoven JJ: Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 21: 1556-1561, 2003.
26. Sørensen JB, Frank H and Palshof T: Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma. Br J Cancer 99: 44-50, 2008.
27. Steele JP, Shamash J, Evans MT, Gower NH, Tischkowitz MD and Rudd RM: Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 18: 3912-3917, 2000.
28. van Haarst JM, Baas P, Manegold C, Schouwink JH, Burgers JA, de Bruin HG, Mooi WJ, van Klaveren RJ, de Jonge MJ and van Meerbeeck JP: Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 86: 342-345, 2002.
29. Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, Mitchell P, Musk AW and Robinson BW: A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 87: 491-496, 2002.
30. Byrne MJ, Davidson JA, Musk AW, Dewar J, Van Hazel G, Buck M, de Klerk NH and Robinson BW: Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study. J Clin Oncol 17: 25-30, 1999.
31. Dowell JE, Dunphy FR, Taub RN, Gerber DE, Ngov L, Yan J, Xie Y and Kindler HL: A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer 77: 567-571, 2012.
32. Jänne PA, Simon GR, Langer CJ, Taub RN, Dowlati A, Fidias P, Monberg M, Obasaju C and Kindler H: Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma. J Clin Oncol 26: 1465-1471, 2008.
33. Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Janne PA, Quinn DI, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato SG, III, Vogelzang NJ, Chen HX, Stadler WM and Vokes EE: Multicenter, double-blind, placebocontrolled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 30: 2509-2515, 2012.
34. Habib EE and Fahmy ES: Chemotherapy management of malignant pleural mesothelioma: A phase II study comparing two popular chemotherapy regimens. Clin Transl Oncol, 2013.
35. Obasaju CK,Ye Z,Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Monberg MJ and Janne PA: Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naive patients with malignant pleural mesothelioma: Outcomes of an expanded access program. Lung Cancer 55: 187-194, 2007.
36. Santoro A, O'Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom S, Liu Y, Ripoche V, Blatter J, Visseren-Grul CM and Manegold C: Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: Results of the International Expanded Access Program. J Thorac Oncol 3: 756-763, 2008.
37. Reck M, Stahel RA, von Pawel J, Karthaus M, Korfee S, Serke M, Schuette WH, Eschbach C, Fink TH, Leschinger MI and Manegold C: Pemetrexed in the treatment of malignant mesothelioma: Results from an expanded access program in Germany. Respir Med 104: 142-148, 2010.
38. Zalcman G, Mazieres J, Scherpereel A, Margery J, Moro-Sibilot D, Parienti J, Gounant V, Riviere A, Monnet I and Molinier O: IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma (MPM). J Clin Oncol 30: abstract TPS7112, 2012.
39. Cordony A, Le Reun C, Smala A, Symanowski JT and Watkins J: Cost-effectiveness of pemetrexed plus cisplatin: Malignant pleural mesothelioma treatment in UK clinical practice. Value Health 11: 4-12, 2008.
40. Woods B, Paracha N, Scott DA and Thatcher N: Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma. Lung Cancer 75: 261-267, 2012.
41. Vogelzang NJ, Symanowski J, Rusthoven J, Manegold C, Boyer B, Nguyen B and Paoletti P: Long-term survival update from the randomized phase III study of pemetrexed plus cisplatin vs. cisplatin in patients with malignant pleural mesothelioma (MPM). Lung Cancer 49: S231, 2005.
42. Ceresoli GL, Castagneto B, Zucali PA, Favaretto A, Mencoboni M, Grossi F, Cortinovis D, Del CG, Ceribelli A, Bearz A, Salamina S, De VF, Cappuzzo F, Marangolo M, Torri V and Santoro A: Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: Combined analysis of two phase II trials. Br J Cancer 99: 51-56, 2008.
43. Ceresoli GL, Zucali PA, Gianoncelli L, Lorenzi E and Santoro A: Second-line treatment for malignant pleural mesothelioma. Cancer Treat Rev 36: 24-32, 2010.
44. Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A and Manegold C: Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 26: 1698-1704, 2008.
45. Sørensen JB, Sundstrom S, Perell K and Thielsen AK: Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment. J Thorac Oncol 2: 147-152, 2007.
46. Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Collova E, Follador A, Lo DM, Moretti A, De VF, Lorenzi E, Perrino M, Giordano L, Farina G, Santoro A and Garassino M: Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey. Lung Cancer 75: 360-367, 2012.
47. Buikhuisen WA, Burgers JA, Vincent AD, Korse CM, van Klaveren RJ, Schramel FM, Pavlakis N, Nowak AK, Custers FL, Schouwink JH, Gans SJ, Groen HJ, Strankinga WF and Baas P: Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): An open-label, multicentre, randomised phase III study. Lancet Oncol 14: 543-551, 2013.
48. Boyer MJ, Jassem J, Liepa AM, Symanowski JT, Kaukel E, Denham CA, Paz-Ares L, Gralla RJ, Hollen PJ and Nguyen B: Symptoms and quality of life advantages for pemetrexed plus cisplatin versus cisplatin in treatment of malignant pleural mesothelioma. Lung Cancer 41: abstract O-56, 2003.
49. Gralla RJ, Hollen PJ, Liepa AM, Symanowski JT, Boyer MJ, Abraham R, Rusthoven JJ, Paz-Ares L and Vogelzang NJ: Improving quality of life in patients with malignant pleural mesothelioma: Results of the randomized pemetrexed plus cisplatin vs. cisplatin trial using the LCSS-meso instrument. Proc Am Soc Clin Oncol 22: abstract 2496, 2003.
50. Guideline for Diagnosis and Treatment of Mesothelioma. 's-Hertogenbosch: Dutch Association of Physicians for Lung Diseases and Tuberculosis (NVALT), 2011 (Richtlijn diagnostiek en behandeling van het mesothelioom).
51. Pharmacotherapeutic Report on Pemetrexed (Alimta®) for the Firstline Treatment of Non-Small Cell Lung Cancer. Diemen: Health Care Insurance Board (CVZ), 2005 (Farmacotherapeutisch rapport pemetrexed (Alimta®) bij de indicatie eerstelijnsbehandeling van niet-kleincellige longkanker).
52. Monitor Expensive Drugs 2008. Costs of Expensive Drugs and Orphan Drugs in the Hospital. Den Haag: Dutch Foundation for Pharmaceutical Statistics (SFK), 2010 (Monitor Dure Geneesmiddelen 2008. Kosten van dure-en weesgeneesmiddelen in het ziekenhuis).
53. Farmatec. CIBG Ministry of Health Welfare and Sport. 2012. Available from: http://www.farmatec.nl. Last accessed June 28, 2013.